Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Peregrine Pharma New (PPHM)

Peregrine Pharma New (PPHM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Peregrine Pharma New 14282 FRANKLIN AVE TUSTIN CA 92780 USA

www.peregrineinc.com P: 714-508-6000

Description:

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus infection. The company is pursuing three separate clinical trials in cancer and HCV infection with its lead product candidate bavituximab and Cotara. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc., which provides development and bio-manufacturing services for both Peregrine and outside customers.

Key Statistics

Overview:

Market Capitalization, $K 190,786
Shares Outstanding, K 45,210
Annual Sales, $ 57,630 K
Annual Net Income, $ -28,160 K
Last Quarter Sales, $ 12,780 K
Last Quarter Net Income, $ -12,620 K
60-Month Beta 2.74
% of Insider Shareholders 2.53%
% of Institutional Shareholders 18.69%

Growth:

1-Year Return 100.95%
3-Year Return -58.99%
5-Year Return -71.29%
5-Year Revenue Growth 278.40%
5-Year Earnings Growth -74.86%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.06 on 09/11/17
Latest Earnings Date 12/11/17
Earnings Per Share ttm -0.77
EPS Growth vs. Prev Qtr -350.00%
EPS Growth vs. Prev Year -92.91%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-7 on 07/10/17

PPHM Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -52.55%
Return-on-Assets % -24.77%
Profit Margin % -48.86%
Debt/Equity 0.00
Price/Sales 3.29
Price/Cash Flow N/A
Price/Book 4.44
Book Value/Share 0.95
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar